ArticleKidney international reports2021
Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes.
Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- First-in-human nuclease-free homologous recombination-dependent gene editing in pediatric patients with methylmalonic acidemia: results of a phase 1/2 study.Gene therapy · 2026Trial
- Thrombotic Microangiopathy Without Thrombocytopenia as a Manifestation of Hypertensive Emergency.International journal of laboratory hematology · 2026Article
- Update in the diagnosis of complement-mediated thrombotic microangiopathy/atypical hemolytic uremic syndrome.Hematology. American Society of Hematology. Education Program · 2025Review
- Toward a Revised Definition of Thrombotic Microangiopathy.Kidney international reports · 2025Article
- A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.Kidney international · 2024Article
- The spectrum of thrombotic microangiopathy related to monoclonal gammopathy.Clinical kidney journal · 2024Article
- Ex Vivo Test of Complement Dysregulation in Atypical Hemolytic Uremic Syndrome Kidney Transplant patients: A Pilot Study.Kidney international reports · 2024Article
- Primary Thrombotic Microangiopathy in Pediatric Patients.Global pediatric health · 2024Article
- The Rationale of Complement Blockade of the MCPInternational journal of molecular sciences · 2023Review
- C3 Glomerulopathy and Thrombotic Microangiopathy: A "Hybrid" Phenotype.Kidney international reports · 2023Article
- Rational use of eculizumab in secondary atypical hemolytic uremic syndrome.Frontiers in immunology · 2023Observational
- Application of C5 inhibitors in glomerular diseases in 2021.Kidney research and clinical practice · 2022Article
- Postsurgical Thrombotic Microangiopathy and Deregulated Complement.Journal of clinical medicine · 2022Article
- The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe syndromes of thrombotic microangiopathy (TMA) are diverse and represent severe endothelial damage caused by various mechanisms. The complement system plays a major role in a subset of patients with TMA, and its recognition is of clinical importance because it guides choice and duration of treatment.
methodsWe studied a well-defined cohort of patients with TMA and hypothesized that assessment of serum-induced
resultsMassive
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.